Travere Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
Hi, everyone. Welcome to the Virtual Vegas Bank of America Health Care Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And it's my pleasure today to welcome Eric Dube, CEO of Travere Therapeutics.
Eric, if you'd like to make any opening remarks, please go ahead, and then we can jump into Q&A.
Great, Greg, and thanks so much for hosting me today. As we are now in May, we had a strong start to the year. And as we look to the future and keep that end in mind that we're working towards, we really aim to bring one of the first treatments for FSGS and IgAN to the many patients who are waiting
(technical difficulty)
for these diseases. In the meantime, we're encouraged by the interim DUPLEX results in FSGS, and we're in the process of engaging with regulators about the submission for this indication.
We're also on track to report interim results from
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |